Disruptive precision medicine technology conquering inflammation and diabetes
Raquel Hontecillas, DVM-PhD
Chief Scientific Officer
- 17 years of translational experience in the biotech industry focusing on infectious, immune-mediated, and metabolic diseases.
- Identified and validated the role of the Lanthionine Synthetase C like 2 (LANCL2) pathway as a key therapeutic target for diabetes and inflammatory bowel disease.
- Expanded Biotherapeutics Inc.‘s product pipeline with other novel targets and therapeutics.
- Published over 100 peer-reviewed papers, 5 patents and manages an R&D portfolio of $15 million.
- Please email me at email@example.com
Back to top